Lista de obras -

A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis

artículo científico publicado en 2019

A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis

artículo científico publicado en 2018

A phase I study of fludarabine, cytarabine, and oxaliplatin therapy in patients with relapsed or refractory acute myeloid leukemia

artículo científico publicado en 2014

A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia.

artículo científico publicado en 2017

A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents

artículo científico publicado en 2018

A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms.

artículo científico publicado en 2017

A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors

artículo científico publicado en 2018

Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia

artículo científico publicado en 2018

Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center

artículo científico publicado en 2005

Allogeneic Transplantation after Myeloablative Rituximab/BEAM ± Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-Up Results

artículo científico publicado en 2019

Atypical cases of necrotizing sweet syndrome in patients with myelodysplastic syndrome and acute myeloid leukaemia

artículo científico publicado en 2020

Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL).

artículo científico publicado en 2014

BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia

artículo científico publicado en 2014

CD123 expression patterns and selective targeting with a CD123-specific antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia

scholarly article by Evgeniya Angelova et al published 25 October 2018 in Haematologica

Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach

artículo científico publicado en 2017

Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage

scientific article published on 11 October 2018

Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring

artículo científico publicado en 2020

Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial

scientific article published on 13 August 2018

Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia

artículo científico publicado en 2018

Clinical Outcomes and Influence of Mutation Clonal Dominance in Oligomonocytic and Classical Chronic Myelomonocytic Leukemia

artículo científico publicado en 2020

Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations

scientific article published on 29 October 2020

Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies

artículo científico publicado en 2017

Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics

artículo científico publicado en 2020

Clonal hematopoiesis of indeterminate potential-associated mutations and risk of comorbidities in patients with myelodysplastic syndrome

artículo científico publicado en 2019

Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study

scientific article published on 01 December 2018

Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors

artículo científico publicado en 2015

Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes

artículo científico publicado en 2015

Development and targeted use of nilotinib in chronic myeloid leukemia.

artículo científico publicado en 2009

Dorsal column myelopathy after intrathecal chemotherapy for leukemia

artículo científico publicado en 2016

Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia.

artículo científico publicado en 2017

Drug evaluation: Nilotinib - a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond.

artículo científico publicado en 2007

Early T precursor acute lymphoblastic leukaemia/lymphoma shows differential immunophenotypic characteristics including frequent CD33 expression and in vitro response to targeted CD33 therapy

artículo científico publicado en 2019

Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia.

artículo científico publicado en 2018

Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE.

artículo científico publicado en 2018

Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States

artículo científico publicado en 2019

Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia

scientific article published on 24 November 2020

Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Non-randomized, Open-label, Phase 2 Study

artículo científico publicado en 2018

Feasibility of Lenalidomide Therapy for Persistent Chronic Lymphocytic Leukemia after Allogeneic Transplantation.

artículo científico publicado en 2017

Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.

artículo científico publicado en 2018

Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen

artículo científico publicado en 2016

GATA3 rs3824662A allele is associated with CRLF2 rearranged B-cell acute lymphoblastic leukemia in adults and adolescents and young adults (AYAs) and is associated with poor prognosis

artículo científico publicado en 2020

Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes

artículo científico publicado en 2020

Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial

scientific article published on 03 May 2019

Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantation

artículo científico publicado en 2019

Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis

artículo científico publicado en 2016

Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial

artículo científico publicado en 2020

Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study

artículo científico publicado en 2019

Impact of TKI maintenance post-allogeneic transplant in Philadelphia positive acute lymphoblastic leukemia

artículo científico publicado en 2020

Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia

artículo científico publicado en 2019

Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors

artículo científico publicado en 2019

Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphobl

scientific article published on 15 April 2019

Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study

artículo científico publicado en 2019

Integrated clinical genotype‐phenotype characteristics of early T‐cell precursor acute lymphoblastic leukemia

artículo científico publicado en 2022

Interferon alpha therapy for patients with essential thrombocythemia: final results of a phase II study initiated in 1986

artículo científico publicado en 2005

Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia

artículo científico publicado en 2021

Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia

scientific article published on 25 September 2019

Long-term results of a phase 2 trial of nilotinib 400 mg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemia

artículo científico publicado en 2020

Long-term results of frontline dasatinib in chronic myeloid leukemia

scientific article published on 30 January 2020

Maintenance therapy in AML: The past, the present and the future

scientific article published on 11 September 2019

Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor: a single-Center experience

scientific article published on 07 December 2020

Management of patients with newly diagnosed chronic myeloid leukemia: opportunities and challenges.

artículo científico publicado en 2007

Myeloid neoplasms with concurrent BCR-ABL1 and CBFB rearrangements: A series of 10 cases of a clinically aggressive neoplasm.

artículo científico publicado en 2017

NPM1 mutant variant allele frequency correlates with leukemia burden but does not provide prognostic information in NPM1-mutated acute myeloid leukemia

artículo científico publicado en 2019

Natural History of Newly Diagnosed Myelodysplastic Syndrome with Isolated Inv(3)/t(3;3)

artículo científico publicado en 2020

Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents

artículo científico publicado en 2017

Novel monoclonal antibody-based treatment strategies in adults with acute lymphoblastic leukemia.

artículo científico publicado en 2019

Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity

scientific article published on 01 July 2007

Optimizing the use of the hyperCVAD regimen: Clinical vignettes and practical management

scientific article published on 03 December 2019

Outcome of adults with relapsed/refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma

artículo científico publicado en 2020

Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium

artículo científico publicado en 2014

Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy

scientific article published on 28 February 2020

Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy

artículo científico publicado en 2019

Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents

scientific article published on 22 December 2015

Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia

artículo científico publicado en 2018

Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML

scientific article published on 08 October 2020

P53 protein overexpression in de novo acute myeloid leukemia patients with normal diploid karyotype correlates with FLT3 internal tandem duplication and worse relapse-free survival

scientific article published on 23 September 2018

PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study

artículo científico publicado en 2007

Patient-reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed/refractory acute lymphoblastic leukemia.

artículo científico publicado en 2018

Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies

artículo científico publicado en 2017

Phase 1/2 study of DFP-10917 administered by continuous intravenous infusion in patients with recurrent or refractory acute myeloid leukemia

scientific article published on 22 January 2019

Phase 2 Study of Hyper-CMAD with Liposomal Vincristine for Patients with Newly Diagnosed Acute Lymphoblastic Leukemia

artículo científico publicado en 2020

Phase I study assessing the safety and tolerability of barasertib (AZD1152) with low-dose cytosine arabinoside in elderly patients with AML

artículo científico publicado en 2013

Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activation

scientific article published on 14 September 2018

Phase I/II Study of Dasatinib in Combination with Decitabine in Patients with Accelerated or Blast Phase Chronic Myeloid Leukemia

artículo científico publicado en 2020

Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia

scientific article published on 20 December 2018

Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality

artículo científico publicado en 2020

Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors

artículo científico publicado en 2019

Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors

scientific article published on 03 March 2020

Practical issues surrounding the explosion of tyrosine kinase inhibitors for the management of chronic myeloid leukemia

artículo científico

Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia

scientific article published on 28 February 2014

Prognosis of patients with intermediate risk IPSS-R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS-R

scientific article published on 26 September 2018

Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients

artículo científico publicado en 2017

Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia

artículo científico publicado en 2016

Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin

artículo científico publicado en 2019

Publisher Correction: Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics

artículo científico publicado en 2020

Recommendations for the Assessment and Management of Measurable Residual Disease in Adults With Acute Lymphoblastic Leukemia: A Consensus of North American Experts

artículo científico publicado en 2018

Relapsed B-acute lymphoblastic leukemia with aberrant myeloperoxidase expression following CAR T-cell therapy: A diagnostic challenge

artículo científico publicado en 2019

Reply to Mini-HCVD plus inotuzumab plus or minus blinatumomab: Hype or hope?

scientific article published on 10 July 2019

Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors

artículo científico publicado en 2013

Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia

scientific article published on 31 August 2018

Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia

scientific article published on 16 July 2019

Survivorship in AML - a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years

artículo científico publicado en 2020

The Clinical Impact of Time to Response in De Novo Accelerated-Phase Chronic Myeloid Leukemia

scientific article published on 17 June 2020

The LEukemia Artificial Intelligence Program (LEAP) in Chronic Myeloid Leukemia in Chronic Phase: A Model to Improve Patient Outcomes

artículo científico publicado en 2020

The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia

artículo científico publicado en 2018

The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival

scientific article published on 19 November 2019

Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients

scientific article published on 14 July 2020

Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia - a distinct subtype with favorable prognosis

scientific article published on 21 September 2020

Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study

artículo científico publicado en 2019

Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis

artículo científico publicado en 2017

Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial

scientific article published on 10 December 2018

Tyrosine kinase inhibition: a therapeutic target for the management of chronic-phase chronic myeloid leukemia

artículo científico publicado en 2013

Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemia

scientific article published on 31 May 2019

Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes

scientific article published on 06 December 2018

Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories

artículo científico publicado en 2018

Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapse

scientific article published on 01 July 2006

Venetoclax with Decitabine Versus Intensive Chemotherapy in Acute Myeloid Leukemia: A Propensity Score Matched Analysis Stratified by Risk of Treatment-related Mortality

scientific article published on 02 December 2020

Lista de obras de

A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis

A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis

A phase I study of fludarabine, cytarabine, and oxaliplatin therapy in patients with relapsed or refractory acute myeloid leukemia

A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia.

A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents

A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms.

A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors

Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia

Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center

Allogeneic Transplantation after Myeloablative Rituximab/BEAM ± Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-Up Results

Atypical cases of necrotizing sweet syndrome in patients with myelodysplastic syndrome and acute myeloid leukaemia

Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL).

BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia

CD123 expression patterns and selective targeting with a CD123-specific antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia

Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach

Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage

Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring

Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial

Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia

Clinical Outcomes and Influence of Mutation Clonal Dominance in Oligomonocytic and Classical Chronic Myelomonocytic Leukemia

Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations

Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies

Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics

Clonal hematopoiesis of indeterminate potential-associated mutations and risk of comorbidities in patients with myelodysplastic syndrome

Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study

Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors

Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes

Development and targeted use of nilotinib in chronic myeloid leukemia.

Dorsal column myelopathy after intrathecal chemotherapy for leukemia

Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia.

Drug evaluation: Nilotinib - a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond.

Early T precursor acute lymphoblastic leukaemia/lymphoma shows differential immunophenotypic characteristics including frequent CD33 expression and in vitro response to targeted CD33 therapy

Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia.

Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE.

Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States

Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia

Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Non-randomized, Open-label, Phase 2 Study

Feasibility of Lenalidomide Therapy for Persistent Chronic Lymphocytic Leukemia after Allogeneic Transplantation.

Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.

Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen

GATA3 rs3824662A allele is associated with CRLF2 rearranged B-cell acute lymphoblastic leukemia in adults and adolescents and young adults (AYAs) and is associated with poor prognosis

Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes

Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial

Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantation

Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis

Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial

Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study

Impact of TKI maintenance post-allogeneic transplant in Philadelphia positive acute lymphoblastic leukemia

Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia

Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors

Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphobl

Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study

Integrated clinical genotype‐phenotype characteristics of early T‐cell precursor acute lymphoblastic leukemia

Interferon alpha therapy for patients with essential thrombocythemia: final results of a phase II study initiated in 1986

Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia

Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia

Long-term results of a phase 2 trial of nilotinib 400 mg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemia

Long-term results of frontline dasatinib in chronic myeloid leukemia

Maintenance therapy in AML: The past, the present and the future

Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor: a single-Center experience

Management of patients with newly diagnosed chronic myeloid leukemia: opportunities and challenges.

Myeloid neoplasms with concurrent BCR-ABL1 and CBFB rearrangements: A series of 10 cases of a clinically aggressive neoplasm.

NPM1 mutant variant allele frequency correlates with leukemia burden but does not provide prognostic information in NPM1-mutated acute myeloid leukemia

Natural History of Newly Diagnosed Myelodysplastic Syndrome with Isolated Inv(3)/t(3;3)

Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents

Novel monoclonal antibody-based treatment strategies in adults with acute lymphoblastic leukemia.

Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity

Optimizing the use of the hyperCVAD regimen: Clinical vignettes and practical management

Outcome of adults with relapsed/refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma

Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium

Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy

Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy

Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents

Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia

Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML

P53 protein overexpression in de novo acute myeloid leukemia patients with normal diploid karyotype correlates with FLT3 internal tandem duplication and worse relapse-free survival

PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study

Patient-reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed/refractory acute lymphoblastic leukemia.

Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies